proxyvotesnow.com

Home › Companies › SANGAMO THERAPEUTICS INC. › 2023-2024

SANGAMO THERAPEUTICS INC. 2023-2024 Proxy Voting Records

Compiled from SEC Form N-PX filings and SANGAMO THERAPEUTICS INC.’s Form 8-K (Item 5.07 on EDGAR). Page generated 02 October 2026.

  • 13Ballot items
  • 143Asset managers
  • 1,726Fund votes
  • 2024-06-04Meeting date

Proxy season: 2023-2024

Explore SANGAMO THERAPEUTICS INC. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by SANGAMO THERAPEUTICS INC.

These tallies are SANGAMO THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

SANGAMO THERAPEUTICS INC. — official shareholder meeting results, meeting held 2024-06-04
Ballot itemForAgainst AbstainWithheldBroker non-votesOutcome
Elect Director: Courtney Beers, PhD. 104,443,77711,180,6531,666,912 --38,717,741 Majority: yes
Elect Director: Robert F. Carey 109,721,8905,869,3131,700,139 --38,717,741 Majority: yes
Elect Director: Kenneth J. Hillan, M.B. 104,440,26711,196,0891,654,986 --38,717,741 Majority: yes
Elect Director: Margaret A. Horn, J.D. 108,722,5556,881,6921,687,095 --38,717,741 Majority: yes
Elect Director: Alexander D. Macrae, M.B., Ch.B., Ph.D. 102,677,99913,424,0261,189,317 --38,717,741 Majority: yes
Elect Director: John H. Markels, Ph.D. 102,086,56913,568,2241,636,549 --38,717,741 Majority: yes
Elect Director: James R. Meyers 103,985,48011,583,3621,722,500 --38,717,741 Majority: yes
Elect Director: H. Stewart Parker 91,662,08723,918,2871,710,968 --38,717,741 Majority: yes
Elect Director: Karen L. Smith, M.D., Ph.D., M.B.A., L.L.M. 104,262,37311,342,8021,686,167 --38,717,741 Majority: yes
Proposal 2: Approval, on an Advisory Basis, of the Compensation of the Named Executive Officers as Disclosed in the Proxy Statement: 101,303,16815,057,209930,965 --38,717,741 Majority: yes
Proposal 3: Approval of the Amended 2018 Plan: 107,523,5578,902,456865,329 --38,717,741 Majority: yes
Proposal 4: Approval of Amendment to Restated Certificate to Increase Authorized Number of Shares of Common Stock: 107,950,3348,623,071717,937 ---- Majority: yes
Proposal 5: Ratification of Appointment of Independent Registered Public Accounting Firm: 151,112,5724,145,949750,562 ---- Majority: yes

Source: SANGAMO THERAPEUTICS INC., Form 8-K — read the filing on EDGAR.

How asset managers voted at the SANGAMO THERAPEUTICS INC. 2023-2024 meeting

Each item below shows how the 143 asset managers that disclosed a SANGAMO THERAPEUTICS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.

1. To approve, on an advisory basis, the compensation of our named executive officers, or NEOs, as described in the accompanying Proxy Statement;

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Combines 8 wordings of this item as funds reported it.

87% Majority: yes · of votes cast

FOR 87%13%
FOR: 101,303,168AGAINST: 15,057,209

SANGAMO THERAPEUTICS INC.’s own tally for this item (“Proposal 2: Approval, on an Advisory Basis, of the Compensation of the Named Executive Officers as Disclosed in the Proxy Statement:”): 101,303,168 for, 15,057,209 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 207,510,076 outstanding shares: 48.8% for, 7% against (56% of the company cast a for/against vote).

The 142 asset managers below cast 99.2% of the shares they voted on this item FOR (106,086,052 for, 802,778 against).

FOR 99.1%
FOR: 106,086,052 (99.2%)AGAINST: 802,778 (0.8%)ABSTAIN: 18,515 (0.0%)NOT VOTED: 75,000 (0.1%)
Largest asset managers voting on “To approve, on an advisory basis, the compensation of our named executive officers, or NEOs, as described in t” at SANGAMO THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
WASATCH ADVISORS LP19,165,5820 00For
ARMISTICE CAPITAL, LLC18,174,9660 00For
WASATCH FUNDS TRUST17,689,3430 00For
Vanguard12,285,7490 00For
BlackRock8,789,5900 00For
Fidelity4,013,2520 00For
GEODE CAPITAL MANAGEMENT, LLC3,302,7910 00For
Charles Schwab2,485,5840 00For
DE Shaw1,913,4200 00For
ACADIAN ASSET MANAGEMENT LLC1,869,4110 00For
State Street1,743,0480 00For
Renaissance1,645,9700 00For
Hudson Bay Capital Management LP1,373,5000 00For
JPMorgan1,319,1200 00For
HighTower Advisors, LLC781,5430 00For
Nuveen737,4640 00For
TIAA716,5280 00For
Northern Trust714,4700 00For
Federated Hermes670,2380 00For
MELLON INVESTMENTS Corp574,8470 00For
Invesco524,1470 00For
Equitable494,2910 00For
T. Rowe Price432,8080 00For
Two Sigma430,4690 00For
Delaware/Macquarie400,0000 00For

Showing the 25 largest of 142 asset managers. See all 142 in the interactive database.

2. To elect the nine nominees for director, named below, to serve on the Board of Directors until the next annual meeting of stockholders to be held in 2025 and until their successors are duly elected and qualified: Alexander D. Macrae, M.B., Ch.B., Ph.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

88% Majority: yes · of votes cast

FOR 88%12%
FOR: 102,677,999AGAINST: 13,424,026

SANGAMO THERAPEUTICS INC.’s own tally for this item (“Elect Director: Alexander D. Macrae, M.B., Ch.B., Ph.D.”): 102,677,999 for, 13,424,026 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 207,510,076 outstanding shares: 49.5% for, 6% against (56% of the company cast a for/against vote).

The 45 asset managers below cast 100% of the shares they voted on this item FOR (42,307,993 for, 0 against).

FOR 99.9%
FOR: 42,307,993 (100.0%)ABSTAIN: 18,515 (0.0%)
Largest asset managers voting on “To elect the nine nominees for director, named below, to serve on the Board of Directors until the next annual” at SANGAMO THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
WASATCH FUNDS TRUST17,689,3430 00For
Vanguard11,788,6050 00For
BlackRock4,123,3960 00For
Fidelity3,564,0090 00For
Charles Schwab1,242,7920 00For
TIAA716,5280 00For
Equitable494,2910 00For
Delaware/Macquarie400,0000 00For
Federated Hermes335,1190 00For
QUANTITATIVE MASTER SERIES LLC254,0250 00For
Invesco241,5620 00For
BRIDGEWAY FUNDS INC195,0000 00For
MFS191,6300 00For
T. Rowe Price154,1040 00For
Lincoln Financial142,1980 00For
AIG/SunAmerica73,4210 00For
Jackson National65,5650 00For
Bridge Builder Trust62,5910 00For
Zacks Trust61,4720 00For
Pacific Life57,8640 00For
Northern Trust54,5110 00For
Voya53,7150 00For
MASTER INVESTMENT PORTFOLIO35,7960 00For
John Hancock35,7600 00For
Principal Exchange-Traded Funds35,5970 00For

Showing the 25 largest of 45 asset managers. See all 45 in the interactive database.

3. To elect the nine nominees for director, named below, to serve on the Board of Directors until the next annual meeting of stockholders to be held in 2025 and until their successors are duly elected and qualified: Courtney Beers, Ph.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

90% Majority: yes · of votes cast

FOR 90%10%
FOR: 104,443,777AGAINST: 11,180,653

SANGAMO THERAPEUTICS INC.’s own tally for this item (“Elect Director: Courtney Beers, PhD.”): 104,443,777 for, 11,180,653 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 207,510,076 outstanding shares: 50.3% for, 5% against (56% of the company cast a for/against vote).

The 45 asset managers below cast 100% of the shares they voted on this item FOR (42,307,993 for, 0 against).

FOR 99.9%
FOR: 42,307,993 (100.0%)ABSTAIN: 18,515 (0.0%)
Largest asset managers voting on “To elect the nine nominees for director, named below, to serve on the Board of Directors until the next annual” at SANGAMO THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
WASATCH FUNDS TRUST17,689,3430 00For
Vanguard11,788,6050 00For
BlackRock4,123,3960 00For
Fidelity3,564,0090 00For
Charles Schwab1,242,7920 00For
TIAA716,5280 00For
Equitable494,2910 00For
Delaware/Macquarie400,0000 00For
Federated Hermes335,1190 00For
QUANTITATIVE MASTER SERIES LLC254,0250 00For
Invesco241,5620 00For
BRIDGEWAY FUNDS INC195,0000 00For
MFS191,6300 00For
T. Rowe Price154,1040 00For
Lincoln Financial142,1980 00For
AIG/SunAmerica73,4210 00For
Jackson National65,5650 00For
Bridge Builder Trust62,5910 00For
Zacks Trust61,4720 00For
Pacific Life57,8640 00For
Northern Trust54,5110 00For
Voya53,7150 00For
MASTER INVESTMENT PORTFOLIO35,7960 00For
John Hancock35,7600 00For
Principal Exchange-Traded Funds35,5970 00For

Showing the 25 largest of 45 asset managers. See all 45 in the interactive database.

4. To elect the nine nominees for director, named below, to serve on the Board of Directors until the next annual meeting of stockholders to be held in 2025 and until their successors are duly elected and qualified: H. Stewart Parker

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

79% Majority: yes · of votes cast

FOR 79%AGAINST 21%
FOR: 91,662,087AGAINST: 23,918,287

SANGAMO THERAPEUTICS INC.’s own tally for this item (“Elect Director: H. Stewart Parker”): 91,662,087 for, 23,918,287 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 207,510,076 outstanding shares: 44% for, 12% against (56% of the company cast a for/against vote).

The 45 asset managers below cast 96% of the shares they voted on this item FOR (40,622,694 for, 1,685,299 against).

FOR 96%
FOR: 40,622,694 (96.0%)AGAINST: 1,685,299 (4.0%)ABSTAIN: 18,515 (0.0%)
Largest asset managers voting on “To elect the nine nominees for director, named below, to serve on the Board of Directors until the next annual” at SANGAMO THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
WASATCH FUNDS TRUST17,689,3430 00For
Vanguard11,722,03766,568 00For
BlackRock4,123,3960 00For
Fidelity3,093,521470,488 00For
Charles Schwab1,242,7920 00For
TIAA716,5280 00For
Equitable256,461237,830 00For
Delaware/Macquarie0400,000 00Against
Federated Hermes335,1190 00For
QUANTITATIVE MASTER SERIES LLC254,0250 00For
Invesco241,5620 00For
BRIDGEWAY FUNDS INC0195,000 00Against
MFS191,6300 00For
T. Rowe Price154,1040 00For
Lincoln Financial142,1980 00For
AIG/SunAmerica073,421 00Against
Jackson National65,5650 00For
Bridge Builder Trust62,5910 00For
Zacks Trust61,4720 00For
Pacific Life57,8640 00For
Northern Trust54,5110 00For
Voya053,715 00Against
MASTER INVESTMENT PORTFOLIO35,7960 00For
John Hancock035,760 00Against
Principal Exchange-Traded Funds035,597 00Against

Showing the 25 largest of 45 asset managers. See all 45 in the interactive database.

5. To elect the nine nominees for director, named below, to serve on the Board of Directors until the next annual meeting of stockholders to be held in 2025 and until their successors are duly elected and qualified: James R. Meyers

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

90% Majority: yes · of votes cast

FOR 90%10%
FOR: 103,985,480AGAINST: 11,583,362

SANGAMO THERAPEUTICS INC.’s own tally for this item (“Elect Director: James R. Meyers”): 103,985,480 for, 11,583,362 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 207,510,076 outstanding shares: 50.1% for, 6% against (56% of the company cast a for/against vote).

The 45 asset managers below cast 100% of the shares they voted on this item FOR (42,307,993 for, 0 against).

FOR 99.9%
FOR: 42,307,993 (100.0%)ABSTAIN: 18,515 (0.0%)
Largest asset managers voting on “To elect the nine nominees for director, named below, to serve on the Board of Directors until the next annual” at SANGAMO THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
WASATCH FUNDS TRUST17,689,3430 00For
Vanguard11,788,6050 00For
BlackRock4,123,3960 00For
Fidelity3,564,0090 00For
Charles Schwab1,242,7920 00For
TIAA716,5280 00For
Equitable494,2910 00For
Delaware/Macquarie400,0000 00For
Federated Hermes335,1190 00For
QUANTITATIVE MASTER SERIES LLC254,0250 00For
Invesco241,5620 00For
BRIDGEWAY FUNDS INC195,0000 00For
MFS191,6300 00For
T. Rowe Price154,1040 00For
Lincoln Financial142,1980 00For
AIG/SunAmerica73,4210 00For
Jackson National65,5650 00For
Bridge Builder Trust62,5910 00For
Zacks Trust61,4720 00For
Pacific Life57,8640 00For
Northern Trust54,5110 00For
Voya53,7150 00For
MASTER INVESTMENT PORTFOLIO35,7960 00For
John Hancock35,7600 00For
Principal Exchange-Traded Funds35,5970 00For

Showing the 25 largest of 45 asset managers. See all 45 in the interactive database.

6. To elect the nine nominees for director, named below, to serve on the Board of Directors until the next annual meeting of stockholders to be held in 2025 and until their successors are duly elected and qualified: John H. Markels, Ph.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

88% Majority: yes · of votes cast

FOR 88%12%
FOR: 102,086,569AGAINST: 13,568,224

SANGAMO THERAPEUTICS INC.’s own tally for this item (“Elect Director: John H. Markels, Ph.D.”): 102,086,569 for, 13,568,224 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 207,510,076 outstanding shares: 49.2% for, 7% against (56% of the company cast a for/against vote).

The 45 asset managers below cast 98% of the shares they voted on this item FOR (41,627,191 for, 680,802 against).

FOR 98%
FOR: 41,627,191 (98.3%)AGAINST: 680,802 (1.6%)ABSTAIN: 18,515 (0.0%)
Largest asset managers voting on “To elect the nine nominees for director, named below, to serve on the Board of Directors until the next annual” at SANGAMO THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
WASATCH FUNDS TRUST17,689,3430 00For
Vanguard11,788,6050 00For
BlackRock4,123,3960 00For
Fidelity3,142,521421,488 00For
Charles Schwab1,242,7920 00For
TIAA716,5280 00For
Equitable494,2910 00For
Delaware/Macquarie400,0000 00For
Federated Hermes335,1190 00For
QUANTITATIVE MASTER SERIES LLC254,0250 00For
Invesco241,5620 00For
BRIDGEWAY FUNDS INC0195,000 00Against
MFS191,6300 00For
T. Rowe Price154,1040 00For
Lincoln Financial142,1980 00For
AIG/SunAmerica73,4210 00For
Jackson National65,5650 00For
Bridge Builder Trust62,5910 00For
Zacks Trust61,4720 00For
Pacific Life57,8640 00For
Northern Trust054,511 00Against
Voya53,7150 00For
MASTER INVESTMENT PORTFOLIO35,7960 00For
John Hancock35,7600 00For
Principal Exchange-Traded Funds35,5970 00For

Showing the 25 largest of 45 asset managers. See all 45 in the interactive database.

7. To elect the nine nominees for director, named below, to serve on the Board of Directors until the next annual meeting of stockholders to be held in 2025 and until their successors are duly elected and qualified: Karen L. Smith, M.D., Ph.D., M.B.A, L.L.M.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

90% Majority: yes · of votes cast

FOR 90%10%
FOR: 104,262,373AGAINST: 11,342,802

SANGAMO THERAPEUTICS INC.’s own tally for this item (“Elect Director: Karen L. Smith, M.D., Ph.D., M.B.A., L.L.M.”): 104,262,373 for, 11,342,802 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 207,510,076 outstanding shares: 50.2% for, 5% against (56% of the company cast a for/against vote).

The 45 asset managers below cast 100% of the shares they voted on this item FOR (42,307,993 for, 0 against).

FOR 99.9%
FOR: 42,307,993 (100.0%)ABSTAIN: 18,515 (0.0%)
Largest asset managers voting on “To elect the nine nominees for director, named below, to serve on the Board of Directors until the next annual” at SANGAMO THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
WASATCH FUNDS TRUST17,689,3430 00For
Vanguard11,788,6050 00For
BlackRock4,123,3960 00For
Fidelity3,564,0090 00For
Charles Schwab1,242,7920 00For
TIAA716,5280 00For
Equitable494,2910 00For
Delaware/Macquarie400,0000 00For
Federated Hermes335,1190 00For
QUANTITATIVE MASTER SERIES LLC254,0250 00For
Invesco241,5620 00For
BRIDGEWAY FUNDS INC195,0000 00For
MFS191,6300 00For
T. Rowe Price154,1040 00For
Lincoln Financial142,1980 00For
AIG/SunAmerica73,4210 00For
Jackson National65,5650 00For
Bridge Builder Trust62,5910 00For
Zacks Trust61,4720 00For
Pacific Life57,8640 00For
Northern Trust54,5110 00For
Voya53,7150 00For
MASTER INVESTMENT PORTFOLIO35,7960 00For
John Hancock35,7600 00For
Principal Exchange-Traded Funds35,5970 00For

Showing the 25 largest of 45 asset managers. See all 45 in the interactive database.

8. To elect the nine nominees for director, named below, to serve on the Board of Directors until the next annual meeting of stockholders to be held in 2025 and until their successors are duly elected and qualified: Kenneth J. Hillan, M.B., Ch.B.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

90% Majority: yes · of votes cast

FOR 90%10%
FOR: 104,440,267AGAINST: 11,196,089

SANGAMO THERAPEUTICS INC.’s own tally for this item (“Elect Director: Kenneth J. Hillan, M.B.”): 104,440,267 for, 11,196,089 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 207,510,076 outstanding shares: 50.3% for, 5% against (56% of the company cast a for/against vote).

The 45 asset managers below cast 100% of the shares they voted on this item FOR (42,307,993 for, 0 against).

FOR 99.9%
FOR: 42,307,993 (100.0%)ABSTAIN: 18,515 (0.0%)
Largest asset managers voting on “To elect the nine nominees for director, named below, to serve on the Board of Directors until the next annual” at SANGAMO THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
WASATCH FUNDS TRUST17,689,3430 00For
Vanguard11,788,6050 00For
BlackRock4,123,3960 00For
Fidelity3,564,0090 00For
Charles Schwab1,242,7920 00For
TIAA716,5280 00For
Equitable494,2910 00For
Delaware/Macquarie400,0000 00For
Federated Hermes335,1190 00For
QUANTITATIVE MASTER SERIES LLC254,0250 00For
Invesco241,5620 00For
BRIDGEWAY FUNDS INC195,0000 00For
MFS191,6300 00For
T. Rowe Price154,1040 00For
Lincoln Financial142,1980 00For
AIG/SunAmerica73,4210 00For
Jackson National65,5650 00For
Bridge Builder Trust62,5910 00For
Zacks Trust61,4720 00For
Pacific Life57,8640 00For
Northern Trust54,5110 00For
Voya53,7150 00For
MASTER INVESTMENT PORTFOLIO35,7960 00For
John Hancock35,7600 00For
Principal Exchange-Traded Funds35,5970 00For

Showing the 25 largest of 45 asset managers. See all 45 in the interactive database.

9. To elect the nine nominees for director, named below, to serve on the Board of Directors until the next annual meeting of stockholders to be held in 2025 and until their successors are duly elected and qualified: Margaret A. Horn, J.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

94% Majority: yes · of votes cast

FOR 94%
FOR: 108,722,555AGAINST: 6,881,692

SANGAMO THERAPEUTICS INC.’s own tally for this item (“Elect Director: Margaret A. Horn, J.D.”): 108,722,555 for, 6,881,692 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 207,510,076 outstanding shares: 52.4% for, 3% against (56% of the company cast a for/against vote).

The 45 asset managers below cast 99% of the shares they voted on this item FOR (41,681,702 for, 626,291 against).

FOR 98%
FOR: 41,681,702 (98.5%)AGAINST: 626,291 (1.5%)ABSTAIN: 18,515 (0.0%)
Largest asset managers voting on “To elect the nine nominees for director, named below, to serve on the Board of Directors until the next annual” at SANGAMO THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
WASATCH FUNDS TRUST17,689,3430 00For
Vanguard11,788,6050 00For
BlackRock4,123,3960 00For
Fidelity3,142,521421,488 00For
Charles Schwab1,242,7920 00For
TIAA716,5280 00For
Equitable494,2910 00For
Delaware/Macquarie400,0000 00For
Federated Hermes335,1190 00For
QUANTITATIVE MASTER SERIES LLC254,0250 00For
Invesco241,5620 00For
BRIDGEWAY FUNDS INC0195,000 00Against
MFS191,6300 00For
T. Rowe Price154,1040 00For
Lincoln Financial142,1980 00For
AIG/SunAmerica73,4210 00For
Jackson National65,5650 00For
Bridge Builder Trust62,5910 00For
Zacks Trust61,4720 00For
Pacific Life57,8640 00For
Northern Trust54,5110 00For
Voya53,7150 00For
MASTER INVESTMENT PORTFOLIO35,7960 00For
John Hancock35,7600 00For
Principal Exchange-Traded Funds35,5970 00For

Showing the 25 largest of 45 asset managers. See all 45 in the interactive database.

10. To elect the nine nominees for director, named below, to serve on the Board of Directors until the next annual meeting of stockholders to be held in 2025 and until their successors are duly elected and qualified: Robert F. Carey

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

95% Majority: yes · of votes cast

FOR 95%
FOR: 109,721,890AGAINST: 5,869,313

SANGAMO THERAPEUTICS INC.’s own tally for this item (“Elect Director: Robert F. Carey”): 109,721,890 for, 5,869,313 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 207,510,076 outstanding shares: 52.9% for, 3% against (56% of the company cast a for/against vote).

The 45 asset managers below cast 100% of the shares they voted on this item FOR (42,307,993 for, 0 against).

FOR 99.9%
FOR: 42,307,993 (100.0%)ABSTAIN: 18,515 (0.0%)
Largest asset managers voting on “To elect the nine nominees for director, named below, to serve on the Board of Directors until the next annual” at SANGAMO THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
WASATCH FUNDS TRUST17,689,3430 00For
Vanguard11,788,6050 00For
BlackRock4,123,3960 00For
Fidelity3,564,0090 00For
Charles Schwab1,242,7920 00For
TIAA716,5280 00For
Equitable494,2910 00For
Delaware/Macquarie400,0000 00For
Federated Hermes335,1190 00For
QUANTITATIVE MASTER SERIES LLC254,0250 00For
Invesco241,5620 00For
BRIDGEWAY FUNDS INC195,0000 00For
MFS191,6300 00For
T. Rowe Price154,1040 00For
Lincoln Financial142,1980 00For
AIG/SunAmerica73,4210 00For
Jackson National65,5650 00For
Bridge Builder Trust62,5910 00For
Zacks Trust61,4720 00For
Pacific Life57,8640 00For
Northern Trust54,5110 00For
Voya53,7150 00For
MASTER INVESTMENT PORTFOLIO35,7960 00For
John Hancock35,7600 00For
Principal Exchange-Traded Funds35,5970 00For

Showing the 25 largest of 45 asset managers. See all 45 in the interactive database.

11. To approve an amendment of our Seventh Amended and Restated Certificate of Incorporation, as amended, or the Restated Certificate, to increase the total number of shares of our common stock authorized for issuance from 640,000,000 to 960,000,000 shares;

CAPITAL STRUCTUREMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

93% Majority: yes · of votes cast

FOR 93%7%
FOR: 107,950,334AGAINST: 8,623,071

SANGAMO THERAPEUTICS INC.’s own tally for this item (“Proposal 4: Approval of Amendment to Restated Certificate to Increase Authorized Number of Shares of Common Stock:”): 107,950,334 for, 8,623,071 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 207,510,076 outstanding shares: 52.0% for, 4% against (56% of the company cast a for/against vote).

The 45 asset managers below cast 99% of the shares they voted on this item FOR (41,886,505 for, 440,003 against).

FOR 99%
FOR: 41,886,505 (99.0%)AGAINST: 440,003 (1.0%)
Largest asset managers voting on “To approve an amendment of our Seventh Amended and Restated Certificate of Incorporation, as amended, or the R” at SANGAMO THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
WASATCH FUNDS TRUST17,689,3430 00For
Vanguard11,788,6050 00For
BlackRock4,123,3960 00For
Fidelity3,142,521421,488 00For
Charles Schwab1,242,7920 00For
TIAA716,5280 00For
Equitable494,2910 00For
Delaware/Macquarie400,0000 00For
Federated Hermes335,1190 00For
QUANTITATIVE MASTER SERIES LLC254,0250 00For
Invesco241,5620 00For
BRIDGEWAY FUNDS INC195,0000 00For
MFS191,6300 00For
T. Rowe Price154,1040 00For
Lincoln Financial142,1980 00For
AIG/SunAmerica73,4210 00For
Jackson National65,5650 00For
Bridge Builder Trust62,5910 00For
Zacks Trust61,4720 00For
Pacific Life57,8640 00For
Northern Trust54,5110 00For
Voya53,7150 00For
MASTER INVESTMENT PORTFOLIO35,7960 00For
John Hancock35,7600 00For
Principal Exchange-Traded Funds35,5970 00For

Showing the 25 largest of 45 asset managers. See all 45 in the interactive database.

12. To approve the amendment and restatement of the Sangamo Therapeutics, Inc. 2018 Equity Incentive Plan, or the 2018 Plan, to, among other things, increase the aggregate number of shares of our common stock reserved for issuance under the 2018 Plan by 11,000,000 shares;

COMPENSATIONMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

92% Majority: yes · of votes cast

FOR 92%8%
FOR: 107,523,557AGAINST: 8,902,456

SANGAMO THERAPEUTICS INC.’s own tally for this item (“Proposal 3: Approval of the Amended 2018 Plan:”): 107,523,557 for, 8,902,456 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 207,510,076 outstanding shares: 51.8% for, 4% against (56% of the company cast a for/against vote).

The 45 asset managers below cast 99.5% of the shares they voted on this item FOR (42,105,620 for, 202,373 against).

FOR 99.4%
FOR: 42,105,620 (99.5%)AGAINST: 202,373 (0.5%)ABSTAIN: 18,515 (0.0%)
Largest asset managers voting on “To approve the amendment and restatement of the Sangamo Therapeutics, Inc. 2018 Equity Incentive Plan, or the ” at SANGAMO THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
WASATCH FUNDS TRUST17,689,3430 00For
Vanguard11,788,6050 00For
BlackRock4,123,3960 00For
Fidelity3,564,0090 00For
Charles Schwab1,242,7920 00For
TIAA716,5280 00For
Equitable494,2910 00For
Delaware/Macquarie400,0000 00For
Federated Hermes335,1190 00For
QUANTITATIVE MASTER SERIES LLC254,0250 00For
Invesco241,5620 00For
BRIDGEWAY FUNDS INC195,0000 00For
MFS0191,630 00Against
T. Rowe Price154,1040 00For
Lincoln Financial142,1980 00For
AIG/SunAmerica73,4210 00For
Jackson National65,5650 00For
Bridge Builder Trust62,5910 00For
Zacks Trust61,4720 00For
Pacific Life57,8640 00For
Northern Trust54,5110 00For
Voya53,7150 00For
MASTER INVESTMENT PORTFOLIO35,7960 00For
John Hancock35,7600 00For
Principal Exchange-Traded Funds35,5970 00For

Showing the 25 largest of 45 asset managers. See all 45 in the interactive database.

13. To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2024

AUDIT-RELATEDMajority of the votes cast: yes

Combines 2 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%
FOR: 151,112,572AGAINST: 4,145,949

SANGAMO THERAPEUTICS INC.’s own tally for this item (“Proposal 5: Ratification of Appointment of Independent Registered Public Accounting Firm:”): 151,112,572 for, 4,145,949 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 207,510,076 outstanding shares: 73% for, 2% against (75% of the company cast a for/against vote).

The 45 asset managers below cast 100% of the shares they voted on this item FOR (42,307,993 for, 0 against).

FOR 99.9%
FOR: 42,307,993 (100.0%)ABSTAIN: 18,515 (0.0%)
Largest asset managers voting on “To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the ye” at SANGAMO THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
WASATCH FUNDS TRUST17,689,3430 00For
Vanguard11,788,6050 00For
BlackRock4,123,3960 00For
Fidelity3,564,0090 00For
Charles Schwab1,242,7920 00For
TIAA716,5280 00For
Equitable494,2910 00For
Delaware/Macquarie400,0000 00For
Federated Hermes335,1190 00For
QUANTITATIVE MASTER SERIES LLC254,0250 00For
Invesco241,5620 00For
BRIDGEWAY FUNDS INC195,0000 00For
MFS191,6300 00For
T. Rowe Price154,1040 00For
Lincoln Financial142,1980 00For
AIG/SunAmerica73,4210 00For
Jackson National65,5650 00For
Bridge Builder Trust62,5910 00For
Zacks Trust61,4720 00For
Pacific Life57,8640 00For
Northern Trust54,5110 00For
Voya53,7150 00For
MASTER INVESTMENT PORTFOLIO35,7960 00For
John Hancock35,7600 00For
Principal Exchange-Traded Funds35,5970 00For

Showing the 25 largest of 45 asset managers. See all 45 in the interactive database.

Largest SANGAMO THERAPEUTICS INC. shareholders voting in 2023-2024

Ranked by the number of SANGAMO THERAPEUTICS INC. shares each manager voted on the most widely held ballot item of the 2023-2024 meeting, shown as a share of the 207,510,076 shares outstanding at the time of that meeting.

Top SANGAMO THERAPEUTICS INC. shareholders by shares voted, 2023-2024
#Asset manager % of shares outstanding
1WASATCH ADVISORS LP 9.24%
2ARMISTICE CAPITAL, LLC 8.76%
3WASATCH FUNDS TRUST 8.52%
4Vanguard 5.92%
5BlackRock 4.24%
6Fidelity 1.93%
7GEODE CAPITAL MANAGEMENT, LLC 1.59%
8Charles Schwab 1.23%
9DE Shaw 0.92%
10ACADIAN ASSET MANAGEMENT LLC 0.90%

Reported SANGAMO THERAPEUTICS INC. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

SANGAMO THERAPEUTICS INC. beneficial owners on record for the 2023-2024 proxy season
Holder % outstanding Disclosure
Armistice Capital, LLC 9.96% DEF14A
Wasatch Advisors, Inc. 9.70% DEF14A
Biogen, Inc. 7.06% DEF14A
Vanguard Group 5.60% 13F
BlackRock 2.20% 13F
Geode Capital 1.62% 13F
Alexander D. Macrae 1.57% DEF14A
Biogen MA Inc. 1.57% 13G
D.E. Shaw 1.48% 13F
State Street 1.33% 13F

Percentages above are of 207,510,076 shares outstanding, as reported by SANGAMO THERAPEUTICS INC. on its Form 10-Q dated 2024-05-06 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from SANGAMO THERAPEUTICS INC.’s 10-Q dated 2024-05-06. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At SANGAMO THERAPEUTICS INC.'s shareholder meeting held 2024-06-04, in the 2023-2024 proxy season, 143 asset managers reported how they voted on 13 ballot items in their SEC Form N-PX filings, covering 1,726 separate fund positions. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of our named executive officers, or NEOs, as… — FOR was 87% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: SANGAMO THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission (filing date not recorded for this item).

SANGAMO THERAPEUTICS INC. proxy season coverage: 2023-2024 (this page).